Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Saroten

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Amitriptylin Testmiljö

Amitriptylin

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Nationella riktlinjer för vård vid depression och ångestsyndrom 2021. Socialstyrelsen [www]. Socialstyrelsen. [updated 2021-04-01, cited 2021-05-14].

  2. LeGates TA, Kvarta MD, Thompson SM. Sex differences in antidepressant efficacy. Neuropsychopharmacology. 2019;44(1):140-154.

  3. Sramek JJ, Murphy MF, Cutler NR. Sex differences in the psychopharmacological treatment of depression. Dialogues Clin Neurosci. 2016;18(4):447-457.

  4. Kerber CS, Dyck MJ, Culp KR, Buckwalter K. Antidepressant treatment of depression in rural nursing home residents. Issues Ment Health Nurs. 2008;29(9):959-73.

  5. Labaka A, Goñi-Balentziaga O, Lebeña A, Pérez-Tejada J. Biological Sex Differences in Depression: A Systematic Review. Biol Res Nurs. 2018;20(4):383-392.

  6. Jalnapurkar I, Allen M, Pigott T. Sex Differences in Anxiety Disorders: A Review. J Psychiatr Depress Anxiety. 2018;4(1):2-9.

  7. Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136(3):380-387.

  8. Vandel S, Vandel B, Sandoz M, Allers G, Bechtel P, Volmat R. Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline. Eur J Clin Pharmacol. 1978;14:185-90.

  9. Jungkunz G, Kuss HJ. On the relationship of nortriptyline: amitriptyline ratio to clinical improvement of amitriptyline treated depressive patients. Pharmakopsychiatr Neuropsychopharmakol. 1980;13:111-6.

  10. Preskorn SH, Mac DS. Plasma levels of amitriptyline: effect of age and sex. J Clin Psychiatry. 1985;46:276-7.

  11. Edelbroek PM, Linssen AC, Zitman FG, Rooymans HG, de Wolff FA. Analgesic and antidepressive effects of low-dose amitriptyline in relation to its metabolism in patients with chronic pain. Clin Pharmacol Ther. 1986;39:156-62.

  12. Rudorfer MV, Robins E. Amitriptyline overdose: clinical effects on tricyclic antidepressant plasma levels. J Clin Psychiatry. 1982;43(11):457-60.

  13. Unterecker S, Riederer P, Proft F, Maloney J, Deckert J, Pfuhlmann B. Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions. J Neural Transm (Vienna). 2013;120(8):1237-46.

  14. Ziegler VE, Biggs JT. Tricyclic plasma levels Effect of age, race, sex, and smoking. JAMA. 1977;238:2167-9.

  15. Martindale: The Complete Drug Reference. Pharmaceutical Press.

  16. Franconi F, Brunelleschi S, Steardo L, Cuomo V. Gender differences in drug responses. Pharmacol Res. 2007;55:81-95.

  17. Nicolson TJ, Mellor HR, Roberts RR. Gender differences in drug toxicity. Trends Pharmacol Sci. 2010;31:108-14.

  18. Wohlfarth T, Storosum JG, Elferink AJ, van Zwieten BJ, Fouwels A, van den Brink W. Response to tricyclic antidepressants: independent of gender?. Am J Psychiatry. 2004;161(2):370-2.

  19. Davidson J, Pelton S. Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res. 1986;17:87-95.

  20. Ziegler DK, Hurwitz A, Hassanein RS, Kodanaz HA, Preskorn SH, Mason J. Migraine prophylaxis A comparison of propranolol and amitriptyline. Arch Neurol. 1987;44:486-9.

  21. Ziegler DK, Hurwitz A, Preskorn S, Hassanein R, Seim J. Propranolol and amitriptyline in prophylaxis of migraine Pharmacokinetic and therapeutic effects. Arch Neurol. 1993;50:825-30.

  22. Vieweg WV, Wood MA. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics. 2004;45:371-7.

  23. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-22.

  24. Chen LW, Chen MY, Lian ZP, Lin HS, Chien CC, Yin HL et al. Amitriptyline and Sexual Function: A Systematic Review Updated for Sexual Health Practice. Am J Mens Health. 2018;12(2):370-379.

  25. Jick SS, Li L. Antidepressant drug use and risk of venous thromboembolism. Pharmacotherapy. 2008;28:144-50.

  26. Vestergaard P, Rejnmark L, Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int. 2008;82:92-101.

  27. Forns J, Pottegård A, Reinders T, Poblador-Plou B, Morros R, Brandt L et al. Antidepressant use in Denmark, Germany, Spain, and Sweden between 2009 and 2014: Incidence and comorbidities of antidepressant initiators. J Affect Disord. 2019;249:242-252.

  28. Bordson SJ, Atayee RS, Ma JD, Best BM. Tricyclic antidepressants: is your patient taking them? Observations on adherence and unreported use using prescriber-reported medication lists and urine drug testing. Pain Med. 2014;15:355-63.

  29. Güloglu C, Orak M, Ustündag M, Altunci YA. Analysis of amitriptyline overdose in emergency medicine. Emerg Med J. 2011;28:296-9.

  30. Dianat S, Zarei MR, Hassanian-Moghaddam H, Rashidi-Ranjbar N, Rahimian R, Rasouli MR. Tricyclic antidepressants intoxication in Tehran, Iran: epidemiology and associated factors. Hum Exp Toxicol. 2011;30:283-8.

  31. Billups SJ, Delate T, Dugan D. Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations. Pharmacoepidemiol Drug Saf. 2009;18:253-7.

  32. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2020 [cited 2021-03-10.]

  1. Nationella riktlinjer för vård vid depression och ångestsyndrom 2021. Socialstyrelsen [www]. Socialstyrelsen. [updated 2021-04-01, cited 2021-05-14].
  2. LeGates TA, Kvarta MD, Thompson SM. Sex differences in antidepressant efficacy. Neuropsychopharmacology. 2019;44(1):140-154.
  3. Sramek JJ, Murphy MF, Cutler NR. Sex differences in the psychopharmacological treatment of depression. Dialogues Clin Neurosci. 2016;18(4):447-457.
  4. Kerber CS, Dyck MJ, Culp KR, Buckwalter K. Antidepressant treatment of depression in rural nursing home residents. Issues Ment Health Nurs. 2008;29(9):959-73.
  5. Labaka A, Goñi-Balentziaga O, Lebeña A, Pérez-Tejada J. Biological Sex Differences in Depression: A Systematic Review. Biol Res Nurs. 2018;20(4):383-392.
  6. Jalnapurkar I, Allen M, Pigott T. Sex Differences in Anxiety Disorders: A Review. J Psychiatr Depress Anxiety. 2018;4(1):2-9.
  7. Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136(3):380-387.
  8. Vandel S, Vandel B, Sandoz M, Allers G, Bechtel P, Volmat R. Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline. Eur J Clin Pharmacol. 1978;14:185-90.
  9. Jungkunz G, Kuss HJ. On the relationship of nortriptyline: amitriptyline ratio to clinical improvement of amitriptyline treated depressive patients. Pharmakopsychiatr Neuropsychopharmakol. 1980;13:111-6.
  10. Preskorn SH, Mac DS. Plasma levels of amitriptyline: effect of age and sex. J Clin Psychiatry. 1985;46:276-7.
  11. Edelbroek PM, Linssen AC, Zitman FG, Rooymans HG, de Wolff FA. Analgesic and antidepressive effects of low-dose amitriptyline in relation to its metabolism in patients with chronic pain. Clin Pharmacol Ther. 1986;39:156-62.
  12. Rudorfer MV, Robins E. Amitriptyline overdose: clinical effects on tricyclic antidepressant plasma levels. J Clin Psychiatry. 1982;43(11):457-60.
  13. Unterecker S, Riederer P, Proft F, Maloney J, Deckert J, Pfuhlmann B. Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions. J Neural Transm (Vienna). 2013;120(8):1237-46.
  14. Ziegler VE, Biggs JT. Tricyclic plasma levels Effect of age, race, sex, and smoking. JAMA. 1977;238:2167-9.
  15. Martindale: The Complete Drug Reference. Pharmaceutical Press.
  16. Franconi F, Brunelleschi S, Steardo L, Cuomo V. Gender differences in drug responses. Pharmacol Res. 2007;55:81-95.
  17. Nicolson TJ, Mellor HR, Roberts RR. Gender differences in drug toxicity. Trends Pharmacol Sci. 2010;31:108-14.
  18. Wohlfarth T, Storosum JG, Elferink AJ, van Zwieten BJ, Fouwels A, van den Brink W. Response to tricyclic antidepressants: independent of gender?. Am J Psychiatry. 2004;161(2):370-2.
  19. Davidson J, Pelton S. Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res. 1986;17:87-95.
  20. Ziegler DK, Hurwitz A, Hassanein RS, Kodanaz HA, Preskorn SH, Mason J. Migraine prophylaxis A comparison of propranolol and amitriptyline. Arch Neurol. 1987;44:486-9.
  21. Ziegler DK, Hurwitz A, Preskorn S, Hassanein R, Seim J. Propranolol and amitriptyline in prophylaxis of migraine Pharmacokinetic and therapeutic effects. Arch Neurol. 1993;50:825-30.
  22. Vieweg WV, Wood MA. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics. 2004;45:371-7.
  23. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-22.
  24. Chen LW, Chen MY, Lian ZP, Lin HS, Chien CC, Yin HL et al. Amitriptyline and Sexual Function: A Systematic Review Updated for Sexual Health Practice. Am J Mens Health. 2018;12(2):370-379.
  25. Jick SS, Li L. Antidepressant drug use and risk of venous thromboembolism. Pharmacotherapy. 2008;28:144-50.
  26. Vestergaard P, Rejnmark L, Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int. 2008;82:92-101.
  27. Forns J, Pottegård A, Reinders T, Poblador-Plou B, Morros R, Brandt L et al. Antidepressant use in Denmark, Germany, Spain, and Sweden between 2009 and 2014: Incidence and comorbidities of antidepressant initiators. J Affect Disord. 2019;249:242-252.
  28. Bordson SJ, Atayee RS, Ma JD, Best BM. Tricyclic antidepressants: is your patient taking them? Observations on adherence and unreported use using prescriber-reported medication lists and urine drug testing. Pain Med. 2014;15:355-63.
  29. Güloglu C, Orak M, Ustündag M, Altunci YA. Analysis of amitriptyline overdose in emergency medicine. Emerg Med J. 2011;28:296-9.
  30. Dianat S, Zarei MR, Hassanian-Moghaddam H, Rashidi-Ranjbar N, Rahimian R, Rasouli MR. Tricyclic antidepressants intoxication in Tehran, Iran: epidemiology and associated factors. Hum Exp Toxicol. 2011;30:283-8.
  31. Billups SJ, Delate T, Dugan D. Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations. Pharmacoepidemiol Drug Saf. 2009;18:253-7.
  32. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2020 [cited 2021-03-10.]